Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)

Hodgkin Lymphoma

All patients will be treated with 6 cycles of BV-EPEM

BrentuximabVedotin (BV)

Institut Català d'Oncologia, Hospital Germans Trias i Pujol

Institut Català d'Oncologia, Hospital Duran i Reynals

Hospital Costa del Sol

Hospital Clinic i Provincial de Barcelona

Hospital Vall d'Hebron

Hospital de Basurto

Hospital General Universitario Gregorio Marañon

Hospital Universitario 12 de Octubre

Hospital Universitario La Paz

Hospital Son Llatzer

Hospital Universitario de Salamanca

Hospital Universitario Donostia - Arantzazu

Hospital Universitario Marqués de Valdecilla

Hospital Universitario Virgen del Rocío

Hospital Universitario Miguel Servet

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)

To identify the maximum tolerated dose (MTD) of Brentuximab Vedotin (BV) in combination with EPEM

To assess the percentage of patients with complete response rate after BV-EPEM treatment.

To evaluate the toxicity of the treatment by measure of number of treatment-related adverse events according to CTCAE v4.0

Evaluation of patient without progression of disease

length of time between date of evidence response and progression of disease or death

To evaluate overall response rate (ORR) based on best response (CR and PR) and the tumor local control rate (CR, PR, and stable disease [SD]) with this treatment regimen.

To assess the type, frequency, severity and relationship of adverse events (AEs) to this treatment regimen.

adriamycin/диария

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Най-пълната база данни за лечебни билки, подкрепена от науката